Journal of Vaccine Research 2024, Vol.14, No.4, 183-195 http://medscipublisher.com/index.php/jvr 193 References Ammi R., Waele J., Willemen Y., Brussel I., Schrijvers D., Lion E., and Smits E.L., 2015, Poly (I: C) as cancer vaccine adjuvant: knocking on the door of medical breakthroughs, Pharmacology and Therapeutics, 146: 120-131. https://doi.org/10.1016/j.pharmthera.2014.09.010 PMid:25281915 Bonam S.R., Partidos C.D., Halmuthur S.K.M., and Muller S., 2017, An overview of novel adjuvants designed for improving vaccine efficacy, Trends in Pharmacological Sciences, 38(9): 771-793. https://doi.org/10.1016/j.tips.2017.06.002 PMid:28668223 Chen F., Wang Y., Gao J., Saeed M., Li T., Wang W., and Yu H., 2021, Nanobiomaterial-based vaccination immunotherapy of cancer, Biomaterials, 270: 120709. https://doi.org/10.1016/j.biomaterials.2021.120709 PMid:33581608 Cuzzubbo S., Mangsbo S., Nagarajan D., Habra K., Pockley A., and McArdle S.E., 2021, Cancer vaccines: Adjuvant potency, importance of age, lifestyle, and treatments, Frontiers in Immunology, 11: 615240. https://doi.org/10.3389/fimmu.2020.615240 PMid:33679703 PMCid:PMC7927599 Del Giudice G., Rappuoli R., and Didierlaurent A.M., 2018, Correlates of adjuvanticity: a review on adjuvants in licensed vaccines, Seminars in Immunology, 39: 14-21. https://doi.org/10.1016/j.smim.2018.05.001 PMid:29801750 den Brok M.H., Nierkens S., Wagenaars J.A., Ruers T.J., Schrier C.C., Rijke E.O., and Adema G.J., 2012, Saponin-based adjuvants create a highly effective anti-tumor vaccine when combined with in situ tumor destruction, Vaccine, 30(4): 737-744. https://doi.org/10.1016/j.vaccine.2011.11.080 PMid:22138178 Du J., Wang C., Xu W., Zhang L., Tang Y., Zhou S., Gao X., Yang G., and Guo J., 2020, Multifunctional protein conjugates with built-in adjuvant (adjuvant-protein-antigen) as cancer vaccines boost potent immune responses, Iscience, 23(3). https://doi.org/10.1016/j.isci.2020.100935 PMid:32146328 PMCid:PMC7063246 Facciolà A., Visalli G., Laganà A., and Pietro A., 2022, An overview of vaccine adjuvants: current evidence and future perspectives, Vaccines, 10(5): 819. https://doi.org/10.3390/vaccines10050819 PMid:35632575 PMCid:PMC9147349 Gouttefangeas C., and Rammensee H.G., 2018, Personalized cancer vaccines: adjuvants are important, too, Cancer Immunology, Immunotherapy, 67(12): 1911-1918. https://doi.org/10.1007/s00262-018-2158-4 PMid:29644387 PMCid:PMC11028305 Heo Y., Ko E., Park S., Park S., Ahn B., Yum J., and Chun E., 2023, L-Pampo™, a Novel TLR2/3 agonist, acts as a potent cancer vaccine adjuvant by activating draining lymph node dendritic cells, Cancers, 15(15): 3978. https://doi.org/10.3390/cancers15153978 PMid:37568794 PMCid:PMC10417701 Hernandez R., and Malek T.R., 2022, Fueling cancer vaccines to improve T cell-mediated antitumor immunity, Frontiers in Oncology, 12: 878377. https://doi.org/10.3389/fonc.2022.878377 PMid:35651800 PMCid:PMC9150178 Ho N.I., Huis in't Veld L.G., Raaijmakers T.K., and Adema G.J., 2018, Adjuvants enhancing cross-presentation by dendritic cells: the key to more effective vaccines?, Frontiers in Immunology, 9: 2874. https://doi.org/10.3389/fimmu.2018.02874 PMid:30619259 PMCid:PMC6300500 Hu H.G., and Li Y.M., 2020, Emerging adjuvants for cancer immunotherapy, Frontiers in Chemistry, 8: 601. https://doi.org/10.3389/fchem.2020.00601 PMid:32850636 PMCid:PMC7406886 Jeon D., Hill E., and McNeel D.G., 2024, Toll-like receptor agonists as cancer vaccine adjuvants, Human Vaccines and Immunotherapeutics, 20(1): 2297453. https://doi.org/10.1080/21645515.2023.2297453 PMid:38155525 PMCid:PMC10760790 Johnston D., and Bystryn J.C., 2006, Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine, Vaccine, 24(11): 1958-1965. https://doi.org/10.1016/j.vaccine.2005.10.045 PMid:16310898 Kaczmarek M., Poznańska J., Fechner F., Michalska N., Paszkowska S., Napierała A., and Mackiewicz A., 2023, Cancer vaccine therapeutics: limitations and effectiveness-A literature review, Cells, 12(17): 2159. https://doi.org/10.3390/cells12172159 PMid:37681891 PMCid:PMC10486481
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==